Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Income from Continuing Operations (2016 - 2025)

Corcept Therapeutics' Income from Continuing Operations history spans 10 years, with the latest figure at 24274000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 21.13% year-over-year to 24274000.0; the TTM value through Dec 2025 reached 99652000.0, down 29.48%, while the annual FY2025 figure was 99652000.0, 29.43% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 24274000.0 at Corcept Therapeutics, up from 19668000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 47243000.0 in Q3 2024 and bottomed at 15834000.0 in Q1 2023.
  • The 5-year median for Income from Continuing Operations is 27660500.0 (2023), against an average of 28052650.0.
  • The largest annual shift saw Income from Continuing Operations soared 89.13% in 2023 before it crashed 58.37% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 32042000.0 in 2021, then plummeted by 48.18% to 16603000.0 in 2022, then surged by 89.13% to 31401000.0 in 2023, then dropped by 1.99% to 30776000.0 in 2024, then decreased by 21.13% to 24274000.0 in 2025.
  • Per Business Quant, the three most recent readings for CORT's Income from Continuing Operations are 24274000.0 (Q4 2025), 19668000.0 (Q3 2025), and 35192000.0 (Q2 2025).